Rituximab mitoxantrone: comparing effectiveness and safety in advanced relapsing multiple sclerosis.

Background: Rituximab (RTX), a CD20 depleting agent, is a frequently used off-label treatment for multiple sclerosis (MS), while mitoxantrone (MTX) is approved, albeit rarely used for active relapsing MS (RMS). However, observational data comparing RTX and MTX effectiveness and safety are scarce.

Objective: We aimed to compare effectiveness and safety of MTX and RTX in patients with active RMS.